A new study has found that the amount of visceral, or belly, fat a person is carrying may be a better predictor of future heart disease risk than their body mass index (BMI) alone

Once seen as a symptom, disrupted sleep is emerging as a modifiable driver of chronic illness. Drugmakers are targeting sleep pathways to reshape chronic disease biology, from pain to depression

Developing treatments for rare diseases presents many challenges: small patient populations, fragmented data and long, complex paths to new therapies. But rare doesn’t mean few. More than 400 million people worldwide live with a rare disease, yet about 95% of the 10,000+ rare diseases don’t have an approved treatment

Through training opportunities and re empowers community members to feel confident supporting refugees. From large private sector to local organizations the training offers information to build trusting relations with refugees and newcomers, in turn building resilience and encouraging clients and patients to seek help for physical and mental health challenges

A sign in front of the entrance of the Security Administration’s main campus on March 19, 2025 in Woodlawn, Maryland. Elon Musk’s Department of Government Efficiency (DOGE) has announced plans to eliminate thousands of agency positions as well as num

SARASOTA, Fla.–(BUSINESS WIRE)–Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced that ‘512 met its primary and all secondary endpoints in a double-blind, placebo-controlled Phase 2 clinical study in adults with inadequately controlled CRSwNP (NCT06930612). ‘512 is known as BEL512 ex-China and CM512 in Greater China